Myovant Sciences registered an amended Form S-1 with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price 13 million shares in the range of $12 to $15 per share, with an overallotment option for an additional 1.95 million shares. At the maximum price the entire offering is valued up to $224.25 million. The shares have been authorized to list on the New York Stock Exchange under the symbol MYOV.
The filing detailed the underwriters of this offering as Citigroup, Cowen, Evercore ISI, Barclays, JMP Securities and Baird.
This is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health diseases and other endocrine-related disorders. Its lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist. The company is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and advanced prostate cancer.
Relugolix has been evaluated in over 1,300 subjects to date, in Phase 1 and multiple large, randomized Phase 2 clinical trials, some of which are ongoing. These trials have produced favorable results in each indication. In these trials, relugolix was shown to be generally well tolerated and to successfully suppress estrogen and progesterone levels in women and testosterone levels in men. The suppression of estrogen and progesterone levels in women has been shown to treat effectively the symptoms of uterine fibroids and endometriosis, and the suppression of testosterone levels in men has been shown to treat effectively advanced prostate cancer.
In a double-blind, placebo-controlled Phase 2 clinical, relugolix posted results that were statistically significant for each treatment arm versus the placebo. Essentially, relugolix markedly decreased menstrual blood loss associated with uterine fibroids.
In two randomized Phase 2 clinical trials in 228 men with advanced prostate cancer, relugolix demonstrated an ability to decrease testosterone to very low levels and to reduce levels of prostate-specific antigen, a key prostate cancer biomarker.
The company intends to use the net proceeds from this offering to further fund its late stage trials of relugolix for multiple indications. The remainder will be used for working capital and general corporate purposes, which may include research and development of relugolix and RVT-602 for other indications.